The US Food and Drug Administration has approved Celgene Corporation's Abraxane paclitaxel protein-bound particles to be used in combination with carboplatin for treating locally advanced or metastatic non-small cell lung cancer among patients who do not respond to curative surgery or radiation therapy.
Abraxane was first approved in 2005 for the treatment of metastatic breast cancer after failure of combination chemotherapy.
"Non-small cell is the most common type of lung cancer, the leading ...
The US Food and Drug Administration has approved Celgene Corporation's Abraxane paclitaxel protein-bound particles to be used in combination with carboplatin for treating locally advanced or metastatic non-small cell lung cancer among patients who do not respond to curative surgery or radiation therapy.
Abraxane was first approved in 2005 for the treatment of metastatic breast cancer after failure of combination chemotherapy.
"Non-small cell is the most common type of lung cancer, the leading ...